サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1720838

神経内分泌がんの世界市場レポート 2025年

Neuroendocrine Carcinoma Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円
神経内分泌がんの世界市場レポート 2025年
出版日: 2025年05月01日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

神経内分泌がん市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.3％で23億3,000万米ドルに成長します。予測期間の成長は、がん罹患率の上昇、製品承認率の上昇、高度な画像診断法の採用拡大、標的治療の拡大、診断・治療選択肢の改善などが牽引するとみられます。主な動向には、診断および画像技術の進歩、標的治療アプローチの開発、神経内分泌腫瘍管理の革新、標的治療および免疫療法の継続的な進歩が含まれます。

標的療法の拡大は神経内分泌がん市場の成長を牽引すると予想されます。標的療法は、特にがんにおいて、疾患進行の原因となる分子プロセスや遺伝子変異を破壊するように設計されています。標的治療薬に対する需要の高まりは、特定の遺伝子変異に対処する精度の高さ、個別化医療の進歩、より少ない副作用で患者の転帰を改善することなどに後押しされています。神経内分泌がん研究は、腫瘍の遺伝的・生化学的プロファイルに沿った標的療法の開発を促進し、治療の正確性と有効性を高める。例えば、2023年7月、米国遺伝子・細胞治療学会（ASGCT）とCitelineは、第II相臨床試験中の遺伝子治療薬の数が2023年第1四半期末の247から2023年第2四半期末には260へと5％増加したと報告しました。この成長は、標的治療戦略への注目が高まっていることを裏付けており、神経内分泌がん市場を牽引しています。

神経内分泌がん市場の主要企業は、治療の精度を高め、患者の転帰を改善するために、標的放射性医薬品治療の進歩に注力しています。標的放射性医薬品治療は、健康な組織へのダメージを最小限に抑えながら、がん細胞に放射線を特異的に照射する放射性分子を使用します。例えば、カナダを拠点とするバイオテクノロジー企業アブデラ・セラピューティクス社は、2024年9月、神経内分泌がんの治療薬ABD-147についてFDAから希少疾病用医薬品の指定を受けた。ABD-147は、小細胞肺がん（SCLC）や大細胞がん（LCNEC）のような侵攻性の神経内分泌がんに多く発現するDLL3タンパク質を発現する腫瘍を選択的に標的とするように設計されています。この指定は、臨床試験の税額控除や潜在的な市場独占権などの重要な利点を提供し、ABD-147をがん領域における有望な治療オプションとして位置づけるものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界神経内分泌がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の神経内分泌がん市場：成長率分析
  • 世界の神経内分泌がん市場の実績：規模と成長, 2019-2024
  • 世界の神経内分泌がん市場の予測：規模と成長, 2024-2029, 2034F
  • 世界神経内分泌がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の神経内分泌がん市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 消化管膵神経内分泌腫瘍
  • カルチノイド腫瘍
  • 褐色細胞腫
  • 髄様甲状腺がん
  • 世界の神経内分泌がん市場診断ツール別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 画像診断
  • 生検
  • 血清学
  • 世界の神経内分泌がん市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 化学療法
  • 放射線療法
  • 手術
  • その他の治療法
  • 世界の神経内分泌がん市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界の神経内分泌がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院
  • クリニック
  • 腫瘍学センター
  • 外来手術センター
  • 世界の神経内分泌がん市場消化管膵神経内分泌腫瘍（GEP-NET）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 膵神経内分泌腫瘍（pNET）
  • 小腸神経内分泌腫瘍
  • 胃神経内分泌腫瘍
  • 大腸神経内分泌腫瘍
  • 世界の神経内分泌がん市場カルチノイド腫瘍の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 肺カルチノイド腫瘍
  • 消化管カルチノイド腫瘍
  • 世界の神経内分泌がん市場褐色細胞腫の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 副腎褐色細胞腫
  • 副腎外傍神経節腫
  • 世界の神経内分泌がん市場髄様甲状腺がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 散発性甲状腺髄様がん
  • 遺伝性甲状腺髄様がん（MEN2関連）

第7章 地域別・国別分析

  • 世界の神経内分泌がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の神経内分泌がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 神経内分泌がん市場：競合情勢
  • 神経内分泌がん市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
    • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Novartis AG
  • Amgen Inc.
  • Boehringer Ingelheim GmbH
  • Exelixis Inc.
  • Lantheus Holdings Inc.
  • HUTCHMED Limited
  • Dana-Farber Cancer Institute Inc.
  • Abdera Therapeutics Inc.
  • Orano Med S.A
  • Eckert & Ziegler Radiopharma GmbH
  • Callisto Pharmaceuticals Inc.
  • RadioMedix Inc.
  • Clarity Pharmaceuticals Limited
  • Delcath Systems Inc.
  • Provectus Biopharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 神経内分泌がん市場2029：新たな機会を提供する国
  • 神経内分泌がん市場2029：新たな機会を提供するセグメント
  • 神経内分泌がん市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34095

Neuroendocrine carcinoma (NEC) is a rare and aggressive cancer that arises from neuroendocrine cells, which possess characteristics of both nerve cells and hormone-producing cells. It is diagnosed and treated to manage tumors that can develop in various organs, including the lungs, pancreas, and gastrointestinal tract, often requiring a combination of surgery, chemotherapy, and targeted therapies.

The primary types of neuroendocrine carcinoma include gastroenteropancreatic neuroendocrine tumors, carcinoid tumors, pheochromocytoma, and medullary thyroid carcinoma. Gastroenteropancreatic neuroendocrine tumors are rare malignancies that originate from neuroendocrine cells in the gastrointestinal tract or pancreas. Diagnosis involves various tools such as imaging, biopsy, and serology, while treatment options include chemotherapy, radiotherapy, surgery, and others. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving end users such as hospitals, clinics, oncology centers, and ambulatory surgery centers.

The neuroendocrine carcinoma market research report is one of a series of new reports from The Business Research Company that provides neuroendocrine carcinoma market statistics, including the neuroendocrine carcinoma industry global market size, regional shares, competitors with the neuroendocrine carcinoma market share, detailed neuroendocrine carcinoma market segments, market trends, and opportunities, and any further data you may need to thrive in the neuroendocrine carcinoma industry. This neuroendocrine carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neuroendocrine carcinoma market size has grown strongly in recent years. It will grow from $1.63 billion in 2024 to $1.76 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period was driven by the expansion of the imaging sector, a rising incidence of neuroendocrine tumors, increasing investments, government initiatives, and growing demand for treatments for neuroendocrine tumors.

The neuroendocrine carcinoma market size is expected to see strong growth in the next few years. It will grow to $2.33 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period is expected to be driven by the rising incidence of cancer, an increasing rate of product approvals, greater adoption of advanced diagnostic imaging methods, the expansion of targeted therapies, and improved diagnosis and treatment options. Key trends include advancements in diagnostic and imaging technologies, the development of targeted treatment approaches, innovations in neuroendocrine tumor management, and continued progress in targeted therapies and immunotherapies.

The expansion of targeted therapies is expected to drive the growth of the neuroendocrine carcinoma market. Targeted therapies are designed to disrupt the molecular processes or genetic mutations responsible for disease progression, particularly in cancer. The increasing demand for targeted therapies is fueled by their precision in addressing specific genetic mutations, advancements in personalized medicine, and improved patient outcomes with fewer side effects. Neuroendocrine carcinoma research facilitates the development of targeted therapies that align with the tumor's genetic and biochemical profiles, enhancing treatment accuracy and effectiveness. For instance, in July 2023, the American Society of Gene & Cell Therapy (ASGCT) and Citeline reported that the number of gene therapies in Phase II clinical trials increased by 5%, from 247 at the end of Q1 2023 to 260 by the end of Q2 2023. This growth underscores the increasing focus on targeted treatment strategies, driving the neuroendocrine carcinoma market.

Leading companies in the neuroendocrine carcinoma market are focusing on advancements in targeted radiopharmaceutical therapy to enhance treatment precision and improve patient outcomes. Targeted radiopharmaceutical therapy uses radioactive molecules that specifically deliver radiation to cancer cells while minimizing damage to healthy tissue. For example, in September 2024, Abdera Therapeutics Inc., a Canada-based biotechnology company, received an orphan drug designation from the FDA for ABD-147 for the treatment of neuroendocrine carcinoma. ABD-147 is designed to selectively target tumors expressing the DLL3 protein, which is commonly upregulated in aggressive neuroendocrine cancers such as small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). This designation provides significant benefits, including tax credits for clinical trials and potential market exclusivity, positioning ABD-147 as a promising treatment option in the field of oncology.

In February 2024, Bristol-Myers Squibb Company, a US-based pharmaceutical company, acquired RayzeBio, Inc. for $4.1 billion. This acquisition aims to strengthen Bristol-Myers Squibb's oncology pipeline, particularly in neuroendocrine tumors and other difficult-to-treat cancers, by leveraging RayzeBio's expertise in targeted therapies and innovative drug development. RayzeBio Inc. is a US-based company specializing in the treatment of gastroenteropancreatic neuroendocrine tumors.

Major players in the neuroendocrine carcinoma market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc.

North America was the largest region in the neuroendocrine carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuroendocrine carcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neuroendocrine carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuroendocrine carcinoma market consists of revenues earned by entities by providing services such as hormonal symptom management, long-term care plans, pain management, immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroendocrine carcinoma market also consists of sales of products including somatostatin analogs, positron emission tomography (PET) scanners, needles and equipment, infusion pumps, and drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuroendocrine Carcinoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neuroendocrine carcinoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neuroendocrine carcinoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neuroendocrine carcinoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Gastroenteropancreatic Neuroendocrine Tumors; Carcinoid Tumors; Pheochromocytoma; Medullary Thyroid Carcinoma
  • 2) By Diagnostic Tools: Imaging; Biopsy; Serology
  • 3) By Treatment: Chemotherapy; Radiotherapy; Surgery; Other Treatments
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • 5) By End-User: Hospitals; Clinics; Oncology Centers; Ambulatory Surgery Centers
  • Subsegments:
  • 1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs); Small Intestinal Neuroendocrine Tumors; Gastric Neuroendocrine Tumors; Colorectal Neuroendocrine Tumors
  • 2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors; Gastrointestinal Carcinoid Tumors
  • 3) By Pheochromocytoma: Adrenal Pheochromocytoma; Extra-Adrenal Paraganglioma
  • 4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma; Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)
  • Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; AstraZeneca plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neuroendocrine Carcinoma Market Characteristics

3. Neuroendocrine Carcinoma Market Trends And Strategies

4. Neuroendocrine Carcinoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Neuroendocrine Carcinoma Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Neuroendocrine Carcinoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Neuroendocrine Carcinoma Market Growth Rate Analysis
  • 5.4. Global Neuroendocrine Carcinoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Neuroendocrine Carcinoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Neuroendocrine Carcinoma Total Addressable Market (TAM)

6. Neuroendocrine Carcinoma Market Segmentation

  • 6.1. Global Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Gastroenteropancreatic Neuroendocrine Tumors
  • Carcinoid Tumors
  • Pheochromocytoma
  • Medullary Thyroid Carcinoma
  • 6.2. Global Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Imaging
  • Biopsy
  • Serology
  • 6.3. Global Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Chemotherapy
  • Radiotherapy
  • Surgery
  • Other Treatments
  • 6.4. Global Neuroendocrine Carcinoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.5. Global Neuroendocrine Carcinoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Clinics
  • Oncology Centers
  • Ambulatory Surgery Centers
  • 6.6. Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pancreatic Neuroendocrine Tumors (pNETs)
  • Small Intestinal Neuroendocrine Tumors
  • Gastric Neuroendocrine Tumors
  • Colorectal Neuroendocrine Tumors
  • 6.7. Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Carcinoid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pulmonary Carcinoid Tumors
  • Gastrointestinal Carcinoid Tumors
  • 6.8. Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Pheochromocytoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Adrenal Pheochromocytoma
  • Extra-Adrenal Paraganglioma
  • 6.9. Global Neuroendocrine Carcinoma Market, Sub-Segmentation Of Medullary Thyroid Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Sporadic Medullary Thyroid Carcinoma
  • Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)

7. Neuroendocrine Carcinoma Market Regional And Country Analysis

  • 7.1. Global Neuroendocrine Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Neuroendocrine Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neuroendocrine Carcinoma Market

  • 8.1. Asia-Pacific Neuroendocrine Carcinoma Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neuroendocrine Carcinoma Market

  • 9.1. China Neuroendocrine Carcinoma Market Overview
  • 9.2. China Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neuroendocrine Carcinoma Market

  • 10.1. India Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neuroendocrine Carcinoma Market

  • 11.1. Japan Neuroendocrine Carcinoma Market Overview
  • 11.2. Japan Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neuroendocrine Carcinoma Market

  • 12.1. Australia Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neuroendocrine Carcinoma Market

  • 13.1. Indonesia Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neuroendocrine Carcinoma Market

  • 14.1. South Korea Neuroendocrine Carcinoma Market Overview
  • 14.2. South Korea Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neuroendocrine Carcinoma Market

  • 15.1. Western Europe Neuroendocrine Carcinoma Market Overview
  • 15.2. Western Europe Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neuroendocrine Carcinoma Market

  • 16.1. UK Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neuroendocrine Carcinoma Market

  • 17.1. Germany Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neuroendocrine Carcinoma Market

  • 18.1. France Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neuroendocrine Carcinoma Market

  • 19.1. Italy Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neuroendocrine Carcinoma Market

  • 20.1. Spain Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neuroendocrine Carcinoma Market

  • 21.1. Eastern Europe Neuroendocrine Carcinoma Market Overview
  • 21.2. Eastern Europe Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neuroendocrine Carcinoma Market

  • 22.1. Russia Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neuroendocrine Carcinoma Market

  • 23.1. North America Neuroendocrine Carcinoma Market Overview
  • 23.2. North America Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neuroendocrine Carcinoma Market

  • 24.1. USA Neuroendocrine Carcinoma Market Overview
  • 24.2. USA Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neuroendocrine Carcinoma Market

  • 25.1. Canada Neuroendocrine Carcinoma Market Overview
  • 25.2. Canada Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neuroendocrine Carcinoma Market

  • 26.1. South America Neuroendocrine Carcinoma Market Overview
  • 26.2. South America Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neuroendocrine Carcinoma Market

  • 27.1. Brazil Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neuroendocrine Carcinoma Market

  • 28.1. Middle East Neuroendocrine Carcinoma Market Overview
  • 28.2. Middle East Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neuroendocrine Carcinoma Market

  • 29.1. Africa Neuroendocrine Carcinoma Market Overview
  • 29.2. Africa Neuroendocrine Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Neuroendocrine Carcinoma Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Neuroendocrine Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neuroendocrine Carcinoma Market Competitive Landscape And Company Profiles

  • 30.1. Neuroendocrine Carcinoma Market Competitive Landscape
  • 30.2. Neuroendocrine Carcinoma Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Neuroendocrine Carcinoma Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Amgen Inc.
  • 31.3. Boehringer Ingelheim GmbH
  • 31.4. Exelixis Inc.
  • 31.5. Lantheus Holdings Inc.
  • 31.6. HUTCHMED Limited
  • 31.7. Dana-Farber Cancer Institute Inc.
  • 31.8. Abdera Therapeutics Inc.
  • 31.9. Orano Med S.A
  • 31.10. Eckert & Ziegler Radiopharma GmbH
  • 31.11. Callisto Pharmaceuticals Inc.
  • 31.12. RadioMedix Inc.
  • 31.13. Clarity Pharmaceuticals Limited
  • 31.14. Delcath Systems Inc.
  • 31.15. Provectus Biopharmaceuticals Inc.

32. Global Neuroendocrine Carcinoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neuroendocrine Carcinoma Market

34. Recent Developments In The Neuroendocrine Carcinoma Market

35. Neuroendocrine Carcinoma Market High Potential Countries, Segments and Strategies

  • 35.1 Neuroendocrine Carcinoma Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Neuroendocrine Carcinoma Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Neuroendocrine Carcinoma Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer